항정신병 약물의 병용요법을 사용 중인 환자들에서 아리피프라졸 장기 지속형 주사제의 효능
Effectiveness of Aripiprazole Long-Acting Injection in Schizophrenia Patients Undergoing Antipsychotic Combination Therapy: A Retrospective Observational Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The aim of this study was to evaluate the effectiveness of aripiprazole long-acting injection in patients with schizophrenia undergoing antipsychotics combination therapy. Methods: We conducted a retrospective analysis using electronic medical records of patients with schizophrenia who initiated aripiprazole long-acting injectable and were treated with antipsychotics combination therapy. These patients were either admitted to a psychiatric hospital or treated as outpatients between June, 2019 and December, 2019. Results: Seventeen patients met the inclusion criteria. The mean number of antipsychotics significantly decreased from 2.53 use to 1.81 at month 12 (p=0.018). Total antipsychotics olanzapine equivalent dose significantly decreased from 46.96 to 27.54 at month 12 (p=0.005). The number of combined medications including antidepressants, mood stabilizers, anxiolytics, and anticholinergics did not significantly change. Both the Positive and Negative Syndrome Scale (PANSS) score and The Global Assessment of Functioning (GAF) score significantly improved until month 24 (p=0.004, 0.038; respectively). Conclusions: This observational study confirmed that aripiprazole long-acting injection is an effective treatment option for patients with schizophrenia undergoing antipsychotic combination therapy. Well-controlled clinical trials are necessary in the near future.
Abstract
Objectives: The aim of this study was to evaluate the effectiveness of aripiprazole long-acting injection in patients with schizophrenia undergoing antipsychotics combination therapy. Methods: We conducted a retrospective analysis using electronic medical records of patients with schizophrenia who initiated aripiprazole long-acting injectable and were treated with antipsychotics combination therapy. These patients were either admitted to a psychiatric hospital or treated as outpatients between June, 2019 and December, 2019. Results: Seventeen patients met the inclusion criteria. The mean number of antipsychotics significantly decreased from 2.53 use to 1.81 at month 12 (p=0.018). Total antipsychotics olanzapine equivalent dose significantly decreased from 46.96 to 27.54 at month 12 (p=0.005). The number of combined medications including antidepressants, mood stabilizers, anxiolytics, and anticholinergics did not significantly change. Both the Positive and Negative Syndrome Scale (PANSS) score and The Global Assessment of Functioning (GAF) score significantly improved until month 24 (p=0.004, 0.038; respectively). Conclusions: This observational study confirmed that aripiprazole long-acting injection is an effective treatment option for patients with schizophrenia undergoing antipsychotic combination therapy. Well-controlled clinical trials are necessary in the near future.
참고문헌 (30)
- Korean Neuropsychiatric Association, "Textbook of Neuropsychiatry", pp.209~240 (2019), iMiS Company Co
- Kahn RS, "Schizophrenia", Nat Rev Dis Primers, 1, pp.15067~ (2015)
- Correll CU, "What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?", World Psychiatry, 17, pp.149~160 (2018)
- Lehman AF, "Practice guideline for the treatment of patients with schizophrenia" (2020), American Psychiatric Association Publishing
- Lee KY, "The long-acting injectable antipsychotics in clinical practice", J Korean Neuropsychiatr Assoc, 58, pp.29~37 (2019)
- Agid O, "Long-acting injectable antipsychotics in the treatment of schizophrenia : their role in relapse prevention", Expert Opin Pharmacother, 11, pp.2301~2317 (2010)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Kane JM, "Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia : a 52-week, multicenter, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 73, pp.617~624 (2012)
- Pae CU, "Effectiveness and tolerability of switching to aripiprazole once monthly from antipsychotic polypharmacy and", or other long acting injectable antipsychotics for patients with schizophrenia in routine practice : a retrospective, observation study, 2020, pp.18, 153~158
- McEvoy JP, "Risks versus benefits of different types of longacting injectable antipsychotics", J Clin Psychiatry, 67(Suppl 5), pp.15~18 (2006)
- Rauch AS, "Long-acting injectable formulations of new-generation antipsychotics : a review from a clinical perspective", CNS Drugs, 27, pp.637~652 (2013)
- "ABILIFY MAINTENA ® (aripiprazole) for extended-release injectable suspension, for intramuscular use"[URL]
- Raoufinia A, "Aripiprazole once-monthly 400mg : comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration", Int J Neuropsychopharmacol, 20, pp.295~304 (2017)
- Cuomo A, "Two-injection start regimen of longacting aripiprazole in 133 patients with schizophrenia", J Clin Psychopharmacol, 43, pp.35~38 (2023)
- Fleischhacker WW, "Aripiprazole once-monthly for treatment of schizophrenia : double-blind, randomised, non-inferiority study", Br J Psychiatry, 205, pp.135~144 (2014)
- Ishigooka J, "Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia : a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole", Schizophr Res, 161, pp.421~428 (2015)
- Naber D, "Qualify : a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia", Schizophr Res, 168, pp.498~504 (2015)
- Fleischhacker WW, "Critical review of antipsychotic polypharmacy in the treatment of schizophrenia", Int J Neuropsychopharmacol, 17, pp.1083~1093 (2014)
- "Haldol decanoate (haloperidol)for IM injection only"[URL]
- "INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use"[URL]
- Gardner DM, "International consensus study of antipsychotic dosing", Am J Psychiatry, 167, pp.686~693 (2010)
- Inada T, "Psychotropic dose equivalence in Japan", Psychiatry Clin Neurosci, 69, pp.440~447 (2015)
- Pae CU, "Clinical benefit and utility of switching to aripiprazole once monthly in patients with antipsychotic polypharmacy or long acting injectable antipsychotics for patients with schizophrenia in routine practice : a retrospective, observation study", Clin Psychopharmacol Neurosci, 19, pp.233~242 (2021)
- Potkin SG, "Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole", Curr Med Res Opin, 29, pp.1241~1251 (2013)
- Kane JM, "Aripiprazole once-monthly in the acute treatment of schizophrenia : findings from a 12-week, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 75, pp.1254~1260 (2014)
- Fleischhacker WW, "Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia", Int Clin Psychopharmacol, 28, pp.171~176 (2013)
- Kane JM, "Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia", J Med Econ, 16, pp.917~925 (2013)
- Aguglia A, "Factors associated with medication adherence to long-acting injectable antipsychotics : results from the STAR network depot study", Pharmacopsychiatry, 55, pp.281~289 (2022)
- Wehring HJ, "Patient and health care provider perspectives on long acting injectable antipsychotics in schizophrenia and the introduction of olanzapine long-acting injection", J Cent Nerv Syst Dis, 2011, pp.107~123 (2011)
- Robinson DG, "Patient and healthcare professional preferences for characteristics of long-acting injectable antipsychotic agents for the treatment of schizophrenia", Adv Ther, 40, pp.2249~2264 (2023)